NEW YORK, NY -- (Marketwire) -- 04/23/12 -- Mergers and Acquisitions have been a hot topic in in the Biotechnology Industry recently. Pharmaceutical giants face an unprecedented number of patent expirations for its pharmaceutical products between 2009 and 2013. It is apparent that pharmaceutical companies have begun to make strategic decisions to combat the anticipated losses. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on Discovery Laboratories, Inc. (NASDAQ: DSCO) and MannKind Corporation (NASDAQ: MNKD).
Access to full reports can be found at:
According to a recent report by Dealogic, pharmaceutical deals totaled $18.5 billion globally this year, an increase of 5% from the same period last year. As larger companies continue to reduce spending on research and development they continue to look at smaller biotech companies to diversify their product lines. Mergers & Acquisitions allows bigger companies to acquire products and technologies that are already proven in the market place, avoiding the many risks associated with research and development.
On Thursday Biotechnology Company Human Genome Sciences rejected a $2.59 billion takeover bid from GlaxoSmithKline. The announcement comes just a day after Swiss pharmaceutical company Roche announced that it was abandoning its bid for U.S. biotech firm Illumina.
Paragon Report releases regular market updates on the Biotechnology Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.ParagonReport.com and get exclusive access to our numerous stock reports and industry newsletters.
Discovery Laboratories, Inc., a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, recently reported financial results for the fourth quarter ended December 31, 2011. For the quarter ended December 31, 2011, the Company reported a net loss of $4.3 million ($0.18 per share) on 24.3 million weighted-average common shares outstanding, compared to a net loss of $5.7 million ($0.42 per share) on 13.5 million weighted-average common shares outstanding for the comparable period in 2010.
MannKind Corporation, a development stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for diabetes and cancer in the United States. Its lead product candidate, AFREZZA inhalation powder, an ultra-rapid acting insulin therapy that is in late-stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia.
Paragon Report provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Paragon Report has not been compensated by any of the above-mentioned companies. We act as independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: